Literature DB >> 2429079

Allosteric modulation of [3H]nitrendipine binding to cardiac and cerebral cortex membranes by amiodarone.

P Nokin, M Clinet, S Swillens, C Delisée, L Meysmans, P Chatelain.   

Abstract

The possible interaction between the antianginal and antiarrhythmic drug amiodarone and the slow calcium channel was investigated by competition binding experiments in guinea-pig cerebral cortex and rat heart membranes using [3H]nitrendipine as radioligand. Amiodarone displaced specifically bound [3H]nitrendipine from cerebral cortex and cardiac membranes in an apparently competitive manner. In saturation binding experiments, apparent affinity for [3H]nitrendipine progressively decreased with increasing concentrations of amiodarone, whereas maximal binding capacity (Bmax remained unchanged. Both diltiazem and verapamil reversed the inhibitory effect of amiodarone on [3H]nitrendipine binding to cerebral cortex membranes. Together these results suggest that amiodarone exerts a pseudocompetitive inhibition on [3H]nitrendipine binding by acting at a site in allosteric interaction with the 1,4 dihydropyridine binding site associated with the calcium channel. The data are compatible with the existence of a common binding site for diltiazem, verapamil, and amiodarone. These observations are discussed in connection with the pharmacological properties of the drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429079     DOI: 10.1097/00005344-198609000-00025

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Actions and mechanisms of action of novel analogues of sotalol on guinea-pig and rabbit ventricular cells.

Authors:  S P Connors; E W Gill; D A Terrar
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

Review 2.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

3.  Characterization of the interaction constants for the binding of two unlabelled ligands to the sites of a receptor. An experimental strategy.

Authors:  S Swillens; A Gourdin; O Delahaut
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-05       Impact factor: 3.000

4.  Amiodarone is a potent calmodulin antagonist.

Authors:  P Nokin; J P Blondiaux; P Schaeffer; L Jungbluth; C Lugnier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-04       Impact factor: 3.000

5.  SR 33557, a novel calcium-antagonist: interaction with [3H]-(+/-)-nitrendipine and [3H]-(-)-desmethoxy-verapamil binding sites in cerebral membranes.

Authors:  P Nokin; M Clinet; P Polster; P Beaufort; L Meysmans; J Gougat; P Chatelain
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

6.  Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart.

Authors:  P Chatelain; L Meysmans; J R Mattéazzi; P Beaufort; M Clinet
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

7.  Identification of a novel calcium antagonist binding site in rat brain by SR 33557.

Authors:  B A Kenny; S Fraser; M Spedding
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.